Legend Biotech's Steep Slide: Is the Cell Therapy Pioneer Now a Value Play?
Legend Biotech shares have plummeted nearly 50% in three months, erasing billions in market value and forcing investors to question whether the selloff is an overreaction or a prudent reassessment of the CAR-T leader's long-term prospects.